OUI Q3 2019 Update
AI@Oxford round up, Oxford Cluster map launched and much more in OUI's regular update.
MiroBio launches with £27m Series A from leading life sciences investors
Oxford spinout developing novel therapeutics based on deep expertise in immune cell regulation.
Herbicide resistance crisis targeted by new Oxford tech firm MoA Technology
MoA Technology, borne out of Oxford University research, launches to confront the global herbicide resistance crisis with £6.3m Series A funding round.
Oxford Brain Diagnostics sets out with the goal of improving the treatment of Alzheimer’s by enabling early and accurate detection
The Oxford University spinout company launches to look inside the brain for novel markers of disease.
Oxford University Innovation Q2 2019 Update
LAB10x launched and AI@Oxford on the horizon in another active quarter for the Oxford Innovation Ecosystem.
Oxford University spinout Zegami secures £1.25m to transform how businesses engage with data
The visual data exploration company charges up for next stage of its evolution.
Whatmore and Grimley join OUI board
Sarah Whatmore and Daniel Grimley join OUI’s Board of Directors, giving the company full divisional representation for the first time in its history.
Oxford University welcomes Osage University Partners to the Oxford innovation ecosystem
Osage University Partners and Oxford University Innovation sign MoU on investment into Oxford University spinouts.
Blue Water Vaccines, developing universal flu vaccine, completes $7m financing following successful preclinical study
Vaccine based on pioneering mathematical models, research from University of Oxford.
Theolytics Limited comes out of stealth mode with Dr Ken Powell announced as Chair of the Board
Virology spinout Theolytics emerges from stealth with £2.5m seed and Dr Ken Powell as chair.
